|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2009-3-9
|
|
pubmed:abstractText |
Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor, improves survival when combined with carboplatin/paclitaxel for advanced nonsquamous non-small-cell lung cancer (NSCLC). This randomized phase III trial investigated the efficacy and safety of cisplatin/gemcitabine (CG) plus bevacizumab in this setting.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:ArcherVeniceV,
pubmed-author:GorbounovaVeraV,
pubmed-author:HirshVeraV,
pubmed-author:LeighlNatashaN,
pubmed-author:ManegoldChristianC,
pubmed-author:MezgerJörgJ,
pubmed-author:MooreNicolaN,
pubmed-author:RamlauRodrygR,
pubmed-author:ReckMartinM,
pubmed-author:ZatloukalPetrP,
pubmed-author:von PawelJoachimJ
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
10
|
|
pubmed:volume |
27
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1227-34
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:19188680-Adult,
pubmed-meshheading:19188680-Aged,
pubmed-meshheading:19188680-Aged, 80 and over,
pubmed-meshheading:19188680-Antibodies, Monoclonal,
pubmed-meshheading:19188680-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:19188680-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19188680-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:19188680-Cisplatin,
pubmed-meshheading:19188680-Deoxycytidine,
pubmed-meshheading:19188680-Female,
pubmed-meshheading:19188680-Humans,
pubmed-meshheading:19188680-Lung Neoplasms,
pubmed-meshheading:19188680-Male,
pubmed-meshheading:19188680-Middle Aged
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.
|
|
pubmed:affiliation |
Department of Thoracic Oncology, Hospital Grosshansdorf, Wohrendamm 80, 22927 Grosshansdorf, Germany. dr.martin.reck@web.de
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase III
|
